Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning ...
Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback